From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting will be held in Orlando, USA. As one of the world’s most influential hematology conferences, ASH gathers leading scholars and clinicians from more than a hundred countries to exchange breakthroughs, clinical insights, and practical experience to shape the future of hematologic disease management.

As both participant and witness to the rapid global progress in hematology, the GoBroad medical team has presented Chinese research findings hundreds of times at major conferences including EHA, ASH, EBMT, and ASCO. This year, 33 GoBroad-led or co-authored studies were selected for ASH, including 3 oral presentations, 29 posters, and 1 abstract. The research spans CAR‑T therapy, hematopoietic stem cell transplantation, pediatric and rare blood diseases, genomic profiling and precision medicine, and expansion of autoimmune disease treatment—demonstrating GoBroad’s long‑term accumulation and innovation driven by clinical needs and patient benefit.

ORAL PRESENTATIONS

Abstract #255

Sequential BCMA and GPRC5D CAR‑T cell therapy combined with an optimized bridging regimen for relapsed/refractory multiple myeloma with bulky extramedullary disease

Beijing GoBroad Boren Hospital

Abstract #672

Prospective phase I/II study of CD19‑directed CAR‑T therapy in relapsed/refractory central nervous system lymphoma

Beijing GoBroad Hospital

Abstract #1053

Impact of hereditary predisposition genes on transplant outcomes and donor selection in hematologic malignancies

Beijing GoBroad Boren Hospital

POSTER PRESENTATIONS

Abstract#1568

Daratumumab and venetoclax-based combined regimen for relapsed/refractory T lymphoblastic leukemia/lymphoma

Abstract#2368

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm open-label phase I study

Abstract#2370

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

Abstract#2377

The ratio of post-infusion circulating PD-1⁺ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Abstract#2386

Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression: A longitudinal multi-omic analysis supporting a paradigm shift in CRS management

Abstract#2427

Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants

Abstract#2467

Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety

Abstract#2529

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy for pediatric relapsed and refractory acute lymphoblastic leukemia followed by TCRαβ-depleted haplo-HSCT

Abstract#3367

Adverse genetic alterations and their prognostic impact in Chinese B-ALL patients with DUX4 rearrangement

Abstract#3526

Impact of ALK Fusion Variants and Genetic Profiles on Prognosis in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma

Abstract#3706

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma

Abstract#3708

CAR-T cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Abstract#4146

SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease

Abstract#4150

Five-year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia

Abstract#4169

Prolonged thrombocytopenia following diverse CAR-T cell therapies: High incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort

Abstract#4190

TBl-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T-cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation

Abstract#4215

Single center evaluation of TCRαβ⁺ T cell depletion using CliniMACS^® Plus platform: Optimizing cell selection for hematopoietic stem cell transplantation

Abstract#4274

Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: A single center in China

Abstract#4281

Superior disease-free survival of allogeneic hematopoietic stem cell transplantation in elderly patients with hematological malignancies in complete remission by reduced-intensity or myeloablative conditioning

Abstract#5107

A prospective non-randomized controlled study of vaseline-medicated gauze for topical management of chemotherapy-induced oral mucositis in pediatric hematology patients

Abstract#5314

The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma

Abstract#5484

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Abstract#5489

Genomic heterogeneity and prognostic implications in CAR-T-treated relapsed/refractory primary CNS lymphoma

Abstract#5933

Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies

Abstract#5934

A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure

Abstract#5948

Unveiling the “second wave”: Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management

Abstract#5989

Study on five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation patients — Achieving zero infection through data-driven and optimized nursing schemes

Abstract#5993

Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases

Abstract#6062

A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRαβ cell depleted HCT

These studies cover advances in CAR‑T therapy mechanisms, biomarkers, safety optimization, bispecific and nanobody engineering, transplantation strategies, pediatric hematology innovations, graft‑versus‑host disease management, immune‑related genetic profiling, viral‑associated CAR‑T expansion patterns, and infection‑control optimization.

ABSTRACT SUMMARY

Abstract :7735

A reduced‑toxicity conditioning regimen using busulfan/fludarabine/cyclophosphamide/anti‑thymocyte globulin for severe aplastic anemia

Facing global challenges in hematologic disease management, the GoBroad team continues to explore safer, more effective, and more accessible therapeutic strategies. With persistent innovation and validated clinical outcomes, GoBroad contributes original Chinese solutions to the international hematology community and will continue collaborating globally to advance patient care and deliver new hope to hematology patients.